Skip to main content
. 2021 Nov 10;11(1):231–248. doi: 10.1007/s40121-021-00545-0

Fig. 1.

Fig. 1

PRISMA flow diagram of screening studies. ANA anakinra, SAR sarilumab, TOC tocilizumab, DEX dexamethasone, HYD hydrocortisone, MET methylprednisolone, BAR baricitinib, RUX ruxolitinib, TOF tofacitinib, SOC standard of care